Ever on the march, Genentech Inc. rounded out the year with another regulatory move, submitting - as promised - a biologics license application for Lucentis against neovascular wet age-related macular degeneration. (BioWorld Today)

Pending final work on labeling and delivery of some preclinical pharmacokinetic data to the FDA, Alkermes Inc. and Cephalon Inc. have won marketing clearance for Vivitrol (formerly Vivitrex), their injectable drug against alcohol dependence. (BioWorld Today)